title: Advances in antifungal therapy.
authors.affiliation: National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Pia S
authors.initials: PS
authors.lastname: Pannaraj
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Walsh
authors.forename: Carol J
authors.initials: CJ
authors.lastname: Baker
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077336:Caspofungin; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D054714:Echinocandins; D005656:Fungal Proteins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D055666:Lipopeptides; D008074:Lipoproteins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000077551:Micafungin; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D005656:Fungal Proteins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D011743:Pyrimidines; D013844:Thiazoles; D014230:Triazoles; C101425:posaconazole; C104066:ER 30346; D000077612:Anidulafungin; C007572:echinocandin B; D000077336:Caspofungin; D065819:Voriconazole; D000077551:Micafungin